Celldex Therapeutics Net Income vs. Current Valuation
| CLDX Stock | USD 23.02 0.52 2.21% |
Net Loss | First Reported 1985-09-30 | Previous Quarter -56.6 M | Current Value -67 M | Quarterly Volatility 16.2 M |
For Celldex Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Celldex Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Celldex Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Celldex Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Celldex Therapeutics over time as well as its relative position and ranking within its peers.
Celldex Therapeutics' Revenue Breakdown by Earning Segment
Check out Trending Equities.
Celldex Therapeutics Revenue Breakdown by Earning Segment
By analyzing Celldex Therapeutics' earnings estimates, investors can diagnose different trends across Celldex Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Celldex Therapeutics. Projected growth potential of Celldex fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Celldex Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (3.38) | Revenue Per Share | Quarterly Revenue Growth (0.71) | Return On Assets | Return On Equity |
Understanding Celldex Therapeutics requires distinguishing between market price and book value, where the latter reflects Celldex's accounting equity. The concept of intrinsic value - what Celldex Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Celldex Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Celldex Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Celldex Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Celldex Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Celldex Therapeutics Current Valuation vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Celldex Therapeutics's current stock value. Our valuation model uses many indicators to compare Celldex Therapeutics value to that of its competitors to determine the firm's financial worth. Celldex Therapeutics is rated fifth in net income category among its peers. It is rated below average in current valuation category among its peers . Celldex Therapeutics reported Net Loss of (142.08 Million) in 2025. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Celldex Therapeutics' earnings, one of the primary drivers of an investment's value.Celldex Current Valuation vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Celldex Therapeutics |
| = | (157.86 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Celldex Therapeutics |
| = | 983.62 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Celldex Current Valuation vs Competition
Celldex Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 15.79 Billion. Celldex Therapeutics holds roughly 983.62 Million in current valuation claiming about 6% of equities under Health Care industry.
Celldex Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Celldex Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Celldex Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Celldex Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Celldex Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 3.8 M | 4 M | |
| Operating Income | -175.6 M | -166.8 M | |
| Income Before Tax | -142.1 M | -135 M | |
| Total Other Income Expense Net | 42.8 M | 44.9 M | |
| Net Loss | -142.1 M | -135 M | |
| Income Tax Expense | -142.1 M | -135 M | |
| Net Loss | -142.1 M | -149.2 M | |
| Non Operating Income Net Other | 580.8 K | 551.7 K | |
| Net Loss | -101.1 M | -106.1 M | |
| Interest Income | 4.8 M | 4.3 M | |
| Change To Netincome | 11 M | 15.7 M | |
| Net Loss | (2.21) | (2.32) | |
| Income Quality | 0.90 | 0.94 | |
| Net Income Per E B T | 1.15 | 1.62 |
Celldex Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Celldex Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Celldex Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Celldex Therapeutics' important profitability drivers and their relationship over time.
Celldex Therapeutics Earnings per Share Projection vs Actual
Use Celldex Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celldex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celldex Therapeutics will appreciate offsetting losses from the drop in the long position's value.Celldex Therapeutics Pair Trading
Celldex Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Celldex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Celldex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Celldex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Celldex Therapeutics to buy it.
The correlation of Celldex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Celldex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Celldex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Celldex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Celldex Therapeutics position
In addition to having Celldex Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Entertainment Thematic Idea Now
Entertainment
Companies from entertainment industry including show business, news and media. The Entertainment theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Entertainment Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.